Last Updated on October 6, 2024 by The Health Master
Drug recall:
Drug recall: Scynexis, Inc. is conducting a voluntary nationwide recall of 2 lots of Brexafemme (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets.
During a review of manufacturing equipment and cleaning activities at a supplier, Scynexis was made aware of potential cross contamination risk with a non-antibacterial beta-lactam drug substance.
This press release provides additional details on the voluntary drug recall recently disclosed by Scynexis.
Risk Statement:
The potential cross contamination with a non-antibacterial beta-lactam drug substance could lead to hypersensitivity reactions such as swelling, rash, urticaria, and anaphylaxis, a potentially life-threatening adverse reaction.
To date, Scynexis has not received any reports of adverse events established to be due to the possible beta-lactam cross contamination.
Drug use:
Brexafemme is an antifungal product indicated for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC).
Brexafemme is dispensed in a carton and packaged in blister packs with four 150-mg tablets (NDC 75788-115-04).
Brexafemme tablet for oral administration is a purple, oval, biconvex shaped, film-coated tablet debossed with 150 on one side and SCY on the other side.
The affected Brexafemme lots include the following lots and expiration dates: LF21000008 (expiration date 11/2023) and LF22000051 (expiration date 11/2025).
The drug recall lots were distributed nationwide to wholesalers across the US, beginning in December 2022.
This drug recall is being conducted with the knowledge of the U.S. Food and Drug Administration (USFDA).
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Drug Recall: Sucralfate Oral Suspension recalled due to this reason
Drug recall: WEFUN Capsules recalled due to presence of undeclared Sildenafil
Drug recall: Novartis recalled Cyclosporine oral solution
Drug recall: Digoxin Tablets recalled due to label mix-up
Drug recall: Glenmark recalls this High BP drug due to quality reasons
Drug recall: Alembic, Aurobindo recall these drugs for this reason
USFDA’s New Inspection Approach for India’s Pharmaceutical Industry
Regulatory Practices: Gujarat FDCA Collaborates with USFDA for Strengthening
GMP Compliance for MSME Pharma Companies: Challenges and Perspectives
Govt issues draft notification for inclusion of Oseltamivir and Zanamivir in Schedule H1
Empowering Teens: New Contraceptive Implant to Combat Teenage Pregnancy
Anti-TB Drugs: Urgent appeal to address critical shortage in India
India’s Pharma-MedTech Sector: New Policy and Scheme unveiled for transforming
Quality Control in Pharma: Understanding the Significance of Dissolution Test
Drug Recall: Sucralfate Oral Suspension recalled due to this reason
Antimicrobial Resistance in India: The Alarming Rise and Potential Solutions –ICMR
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
